The Effects of a New Thromboxane Synthetase Inhibitor, CGS‐13080, in Man
作者:
MALCOLM W. MACNAB,
E. L. FOLTZ,
BETTY S. GRAVES,
ROY K. RINEHART,
SPENCER L. TRIPP,
NANCY R. FELICIANO,
SUPRADIP SEN,
期刊:
The Journal of Clinical Pharmacology
(WILEY Available online 1984)
卷期:
Volume 24,
issue 2‐3
页码: 76-83
ISSN:0091-2700
年代: 1984
DOI:10.1002/j.1552-4604.1984.tb02768.x
出版商: Blackwell Publishing Ltd
数据来源: WILEY
摘要:
Abstract:CGS‐13080 is a new potent selective inhibitor of thromboxane synthetase. This study reports the results of a safety and efficacy study of single oral doses in normal healthy volunteers. The compound was well tolerated by all subjects without evidence of any adverse reactions. Serum thromboxane B2levels (the stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximal effect of a 99 per cent reduction occurring at 0.5 and 1 hour after administration. There was a concomitant increase in PGE2and 6‐keto‐PGF1α(the stable metabolic product of PGI2), suggesting a shunting of cyclic endoperoxide metabolism. The apparent half‐life of the compound is about 1 hour, but return to 50 percent of the original thromboxane B2levels was achieved between 4 and 6 hours. Platelet aggregation to collagen and bleeding times failed to demonstrate significant changes after drug administration. Bleeding times showed a slight increase 2 hours after administration of the
点击下载:
PDF
(884KB)
返 回